Is Turoctocog alfa pegol registered with the SFDA?

The SFDA human drug list (edition 4-2026, as published by the Council of Health Insurance) lists 2 valid registrations of Turoctocog alfa pegol, including Esperoct (500 IU, Powder and solvent for solution for injection, SAR 1504.75); Esperoct (1000 IU, Powder and solvent for solution for injection, SAR 3009.55).

Is Turoctocog alfa pegol authorised in the European Union?

EMA lists 1 centrally authorised medicine containing Turoctocog alfa pegol: Esperoct.

Active substance

Turoctocog alfa pegol

SFDA 5
EMA 1

Open in the medicines table

SFDA Saudi Arabia — SFDA human drug list

Trade name	Strength	Form · route	Pack	Public price	Type	Company	Status
Esperoct	500 IU	Powder and solvent for solution for injection · Intravenous use	1 Pre-filled syringe	SAR 1504.75	Biological · Prescription	NOVO NORDISK	Valid
Esperoct	1000 IU	Powder and solvent for solution for injection · Intravenous use	1 Pre-filled syringe	SAR 3009.55	Biological · Prescription	NOVO NORDISK	Valid
Esperoct	1500 IU	Powder and solvent for solution for injection · Intravenous use	1 Pre-filled syringe	SAR 4514.30	Biological · Prescription	NOVO NORDISK	Withdrawn by MAH · Not Marketed
Esperoct	2000 IU	Powder and solvent for solution for injection · Intravenous use	1 Pre-filled syringe	SAR 6019.10	Biological · Prescription	NOVO NORDISK	Withdrawn by MAH · Not Marketed
Esperoct	3000 IU	Powder and solvent for solution for injection · Intravenous use	1 Pre-filled syringe	SAR 9028.65	NCE · Prescription	NOVO NORDISK	Withdrawn by MAH · Not Marketed

EMA European Union — centrally authorised medicines

Esperoct Novo Nordisk A/S · Authorised · authorised 20 Jun 2019 · ATC B02BD02

Therapeutic indication (EMA)

Treatment and prophylaxis of bleeding in patients with haemophilia A (congenital factor VIII deficiency).Esperoct can be used for all age groups.

Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.